ATE121735T1 - 2,4-diaminochinazolin-derivate, um die antitumorwirkung zu erhöhen. - Google Patents

2,4-diaminochinazolin-derivate, um die antitumorwirkung zu erhöhen.

Info

Publication number
ATE121735T1
ATE121735T1 AT92903632T AT92903632T ATE121735T1 AT E121735 T1 ATE121735 T1 AT E121735T1 AT 92903632 T AT92903632 T AT 92903632T AT 92903632 T AT92903632 T AT 92903632T AT E121735 T1 ATE121735 T1 AT E121735T1
Authority
AT
Austria
Prior art keywords
antitumor effect
increase antitumor
diaminoquinazoline derivatives
diaminoquinazoline
derivatives
Prior art date
Application number
AT92903632T
Other languages
English (en)
Inventor
Jotham W Coe
Anton F J Fliri
Takushi Kaneko
Eric R Larson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE121735T1 publication Critical patent/ATE121735T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT92903632T 1991-02-20 1992-01-08 2,4-diaminochinazolin-derivate, um die antitumorwirkung zu erhöhen. ATE121735T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65792291A 1991-02-20 1991-02-20

Publications (1)

Publication Number Publication Date
ATE121735T1 true ATE121735T1 (de) 1995-05-15

Family

ID=24639196

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92903632T ATE121735T1 (de) 1991-02-20 1992-01-08 2,4-diaminochinazolin-derivate, um die antitumorwirkung zu erhöhen.

Country Status (23)

Country Link
EP (1) EP0572437B1 (de)
JP (1) JPH06500117A (de)
KR (1) KR930703270A (de)
CN (1) CN1064271A (de)
AT (1) ATE121735T1 (de)
AU (1) AU655798B2 (de)
BR (1) BR9205645A (de)
CA (1) CA2101542A1 (de)
CZ (1) CZ387292A3 (de)
DE (2) DE9290018U1 (de)
DK (1) DK0572437T3 (de)
ES (1) ES2071484T3 (de)
FI (1) FI933656L (de)
HU (1) HUT64755A (de)
IE (1) IE920522A1 (de)
IL (1) IL100942A0 (de)
MX (1) MX9200675A (de)
NO (1) NO932954L (de)
NZ (1) NZ241627A (de)
PT (1) PT100132A (de)
WO (1) WO1992014716A1 (de)
YU (1) YU17092A (de)
ZA (1) ZA921911B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
ES2049659B1 (es) * 1992-10-08 1994-10-16 Ici Plc Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE4429026C2 (de) * 1994-08-16 1995-11-16 Mueller Wolfgang Inlay-Entfernungsinstrumentarium für Totalendoprothese
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
DE69613367T2 (de) * 1995-04-27 2002-04-18 Astrazeneca Ab, Soedertaelje Chinazolin derivate
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
AU7692896A (en) * 1995-12-01 1997-06-27 Novartis Ag Quinazolin-2,4-diazirines as NPY receptor antagonist
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DK0880508T3 (da) 1996-02-13 2003-06-30 Astrazeneca Ab Quinazolinderivater som VEGF-inhibitorer
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP1676845B1 (de) 1999-11-05 2008-06-11 AstraZeneca AB Neue Quinazolin-Derivate
AU2001240150A1 (en) * 2000-03-13 2001-09-24 Chemrx Advanced Technologies, Inc. Quinazoline synthesis
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
WO2006074147A2 (en) * 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
JP2007269629A (ja) * 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
US20060025406A1 (en) * 2004-07-06 2006-02-02 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c- Met activity
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
JP2008526776A (ja) * 2005-01-03 2008-07-24 ミリアド ジェネティクス， インコーポレイテッド 脳癌の治療の方法
WO2007065913A1 (en) * 2005-12-07 2007-06-14 Neurosearch A/S Novel quinazoline-2,4-diamine derivatives and their use as modulators of small-conductance calcium-activated potassium channels
CN101100466B (zh) 2006-07-05 2013-12-25 天津和美生物技术有限公司 不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用
US20090004185A1 (en) * 2007-01-11 2009-01-01 Wyeth Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/tcf-4 pathway and cancer treatment agents
EP2173346A2 (de) * 2007-06-27 2010-04-14 Summit Corporation Plc Verwendung von verbindungen zur herstellung von anti-tuberkulose-mitteln
WO2011140527A2 (en) * 2010-05-07 2011-11-10 California Institute Of Technology And The University Of Kansas Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase
WO2018212774A1 (en) * 2017-05-17 2018-11-22 Vanderbilt University Quinazoline compounds as modulators of ras signaling

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663706A (en) * 1969-09-29 1972-05-16 Pfizer Use of 2,4-diaminoquinazolines as hypotensive agents
IL88507A (en) * 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them
AU610328B2 (en) * 1987-12-03 1991-05-16 Smithkline Beckman Intercredit B.V. 2,4- diaminoquinazoline derivatives

Also Published As

Publication number Publication date
ZA921911B (en) 1993-08-19
BR9205645A (pt) 1994-06-07
DE69202243D1 (de) 1995-06-01
JPH06500117A (ja) 1994-01-06
FI933656A0 (fi) 1993-08-19
ES2071484T3 (es) 1995-06-16
HU9302384D0 (en) 1993-11-29
HUT64755A (en) 1994-02-28
YU17092A (sh) 1994-12-28
NO932954D0 (no) 1993-08-19
WO1992014716A1 (en) 1992-09-03
DE9290018U1 (de) 1993-10-14
AU1184892A (en) 1992-09-15
KR930703270A (ko) 1993-11-29
EP0572437A1 (de) 1993-12-08
FI933656A7 (fi) 1993-08-19
PT100132A (pt) 1993-05-31
DK0572437T3 (da) 1995-07-03
CZ387292A3 (en) 1994-04-13
NO932954L (no) 1993-08-19
MX9200675A (es) 1992-08-01
CN1064271A (zh) 1992-09-09
FI933656L (fi) 1993-08-19
NZ241627A (en) 1993-06-25
DE69202243T2 (de) 1995-08-31
IL100942A0 (en) 1992-11-15
IE920522A1 (en) 1992-08-26
AU655798B2 (en) 1995-01-12
CA2101542A1 (en) 1992-08-21
EP0572437B1 (de) 1995-04-26

Similar Documents

Publication Publication Date Title
ATE121735T1 (de) 2,4-diaminochinazolin-derivate, um die antitumorwirkung zu erhöhen.
ATE124694T1 (de) Chinazolinderivate um die antitumorwirkung zu verbessern.
IN170909B (de)
FI952248L (fi) Kasvainvastaisia koostumuksia, jotka sisältävät taksaanijohdannaisia
DE3863442D1 (de) Sukroseester enthaltende, die hautpermeabilitaet vergroessernde zusammensetzungen.
DE69103503D1 (de) Adriamycinderivate.
DE3782182D1 (de) Azacycloalkanderivate, absorptionspromotoren, die die derivate als effektiven inhaltsstoff enthalten und aeusserlich anzuwendende praeparate, die absorptionspromotoren enthalten.
MX9201763A (es) Derivados de pirimidina para aumentar la actividad antitumores.
DE68912818D1 (de) Antitumormittel.
DE69003257D1 (de) Tetralin-Derivate.
DE3781847D1 (de) Pyrimidinderivate, ihre herstellung und medikamente die diese derivate enthalten.
NO883070D0 (no) 4-aminosubstituerte 1,2-dihydroksynaftalin-derivater.
DE69034209D1 (de) 2'-deoxy-4'-thioribonucleoside als antivirale und antikrebsmittel
CA1265159C (en) GEM-DIHALOGENO-1,8-DIAMINO-4-AZA-OCTANES
RU93054001A (ru) 2,4-диаминохиназолиновые производные, способ их получения фармацевтическая композиция, способ ингибирования р-гликопротеина
ATE179987T1 (de) Vitamin b 12-haltige sanddornkonzentrate oder - extrakte
IT8433323V0 (it) Spiralex maxima securitas 2000 n. 3cu 213,33 mg.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee